191 related articles for article (PubMed ID: 38163957)
1. Systemic Sclerosis and Atherosclerosis: Potential Cellular Biomarkers and Mechanisms.
Gerasimova EV; Shayakhmetova RU; Gerasimova DA; Popkova TV; Ananyeva LP
Front Biosci (Schol Ed); 2023 Dec; 15(4):16. PubMed ID: 38163957
[TBL] [Abstract][Full Text] [Related]
2. The role of endothelial cells in the vasculopathy of systemic sclerosis: A systematic review.
Mostmans Y; Cutolo M; Giddelo C; Decuman S; Melsens K; Declercq H; Vandecasteele E; De Keyser F; Distler O; Gutermuth J; Smith V
Autoimmun Rev; 2017 Aug; 16(8):774-786. PubMed ID: 28572048
[TBL] [Abstract][Full Text] [Related]
3. Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of Systemic Sclerosis-associated pulmonary fibrosis and pulmonary arterial hypertension. Myth or reality?
Jimenez SA; Piera-Velazquez S
Matrix Biol; 2016 Apr; 51():26-36. PubMed ID: 26807760
[TBL] [Abstract][Full Text] [Related]
4. Atherosclerosis and macrovascular involvement in systemic sclerosis: myth or reality.
Nussinovitch U; Shoenfeld Y
Autoimmun Rev; 2011 Mar; 10(5):259-66. PubMed ID: 20863903
[TBL] [Abstract][Full Text] [Related]
5. Is atherosclerosis accelerated in systemic sclerosis? Novel insights.
Soriano A; Afeltra A; Shoenfeld Y
Curr Opin Rheumatol; 2014 Nov; 26(6):653-7. PubMed ID: 25198242
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular disease in systemic sclerosis--an emerging association?
Ngian GS; Sahhar J; Wicks IP; Van Doornum S
Arthritis Res Ther; 2011 Aug; 13(4):237. PubMed ID: 21888685
[TBL] [Abstract][Full Text] [Related]
7. Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis.
Manetti M; Romano E; Rosa I; Guiducci S; Bellando-Randone S; De Paulis A; Ibba-Manneschi L; Matucci-Cerinic M
Ann Rheum Dis; 2017 May; 76(5):924-934. PubMed ID: 28062404
[TBL] [Abstract][Full Text] [Related]
8. Endothelial-to-mesenchymal transition in systemic sclerosis.
Di Benedetto P; Ruscitti P; Berardicurti O; Vomero M; Navarini L; Dolo V; Cipriani P; Giacomelli R
Clin Exp Immunol; 2021 Jul; 205(1):12-27. PubMed ID: 33772754
[TBL] [Abstract][Full Text] [Related]
9. Myofibroblast induction and microvascular alteration in scleroderma lung fibrosis.
Beon M; Harley RA; Wessels A; Silver RM; Ludwicka-Bradley A
Clin Exp Rheumatol; 2004; 22(6):733-42. PubMed ID: 15638048
[TBL] [Abstract][Full Text] [Related]
10. Characterization of Vascular Niche in Systemic Sclerosis by Spatial Proteomics.
Rius Rigau A; Li YN; Matei AE; Györfi AH; Bruch PM; Koziel S; Devakumar V; Gabrielli A; Kreuter A; Wang J; Dietrich S; Schett G; Distler JHW; Liang M
Circ Res; 2024 Mar; 134(7):875-891. PubMed ID: 38440901
[TBL] [Abstract][Full Text] [Related]
11. Endothelial dysfunction precedes atherosclerosis in systemic sclerosis--relevance for prevention of vascular complications.
Szucs G; Tímár O; Szekanecz Z; Dér H; Kerekes G; Szamosi S; Shoenfeld Y; Szegedi G; Soltész P
Rheumatology (Oxford); 2007 May; 46(5):759-62. PubMed ID: 17244666
[TBL] [Abstract][Full Text] [Related]
12. Early inflammatory players in cutanous fibrosis.
Raker V; Haub J; Stojanovic A; Cerwenka A; Schuppan D; Steinbrink K
J Dermatol Sci; 2017 Sep; 87(3):228-235. PubMed ID: 28655471
[TBL] [Abstract][Full Text] [Related]
13. A loss of telocytes accompanies fibrosis of multiple organs in systemic sclerosis.
Manetti M; Rosa I; Messerini L; Guiducci S; Matucci-Cerinic M; Ibba-Manneschi L
J Cell Mol Med; 2014 Feb; 18(2):253-62. PubMed ID: 24467430
[TBL] [Abstract][Full Text] [Related]
14. The role of asymmetric dimethylarginine in endothelial dysfunction and abnormal nitric oxide metabolism in systemic sclerosis: results from a pilot study.
Pagkopoulou E; Soulaidopoulos S; Katsiki N; Malliari A; Loutradis C; Karagiannis A; Doumas M; Garyfallos A; Kitas G; Dimitroulas T
Clin Rheumatol; 2023 Apr; 42(4):1077-1085. PubMed ID: 36534350
[TBL] [Abstract][Full Text] [Related]
15. Systemic sclerosis.
Asano Y
J Dermatol; 2018 Feb; 45(2):128-138. PubMed ID: 29226387
[TBL] [Abstract][Full Text] [Related]
16. The immunopathogenesis of fibrosis in systemic sclerosis.
Brown M; O'Reilly S
Clin Exp Immunol; 2019 Mar; 195(3):310-321. PubMed ID: 30430560
[TBL] [Abstract][Full Text] [Related]
17. Pathogenesis of vasculopathy in systemic sclerosis and its contribution to fibrosis.
Kawaguchi Y; Kuwana M
Curr Opin Rheumatol; 2023 Nov; 35(6):309-316. PubMed ID: 37490353
[TBL] [Abstract][Full Text] [Related]
18. Role of microRNA in the pathogenesis of systemic sclerosis tissue fibrosis and vasculopathy.
Henry TW; Mendoza FA; Jimenez SA
Autoimmun Rev; 2019 Nov; 18(11):102396. PubMed ID: 31520794
[TBL] [Abstract][Full Text] [Related]
19. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
Front Immunol; 2020; 11():1990. PubMed ID: 33013852
[TBL] [Abstract][Full Text] [Related]
20. Endothelial/lymphocyte activation leads to prominent CD4+ T cell infiltration in the gastric mucosa of patients with systemic sclerosis.
Manetti M; Neumann E; Müller A; Schmeiser T; Saar P; Milia AF; Endlicher E; Roeb E; Messerini L; Matucci-Cerinic M; Ibba-Manneschi L; Müller-Ladner U
Arthritis Rheum; 2008 Sep; 58(9):2866-73. PubMed ID: 18759276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
